The Spanish pharmaceutical company PharmaMar made it known that its partner in South Korea, Boryung Pharmaceutical, has had positive results with lto application of Aplidin in cell cultures. With the different experiments carried out by this company, the expectation is that this chemical compound will be reduced the progression of the disease to Acute Respiratory Distress Syndrome, improving the health of patients who are hospitalized due to COVID-19. However, More research is still needed to apply this to people infected with SARS-CoV-2.
What is the medicine Aplidin?
The results of Aplidin in cell samples have shown that the drug effectively prevents and fights the virus, it also has an activity 80 times greater than remdesivir, a drug that has already been approved to start its clinical trial in people in the European region.
What is Aplidin, the medicine that could end the coronavirus? What is Aplidin, the medicine that could end the coronavirus?
Getty Image
“According to data on antiviral activity obtained in the SARS-CoV2 study in the” Vero “cell model (monkey kidney cell) by a reputed Korean research laboratory, and requested by Boryung Pharmaceutical, Plitidepsin has shown antiviral activity between 2,400 and 2,800 times greater than remdesivir (approved as the drug COVID-19 in Korea), and also an activity 80 times greater than that of Remdesivir in the “Calu-3” cell model (human lung cell). “, PharmaMar says in its statement
Preparations for clinical trials with Aplidin in Korea are expected to begin in the third quarter of 2020.. “With these potent antiviral activity data, we hope to reduce disease progression to Acute Respiratory Distress Syndrome (ARDS) in hospitalized patients with covid-19 pneumonia, along with rapid improvement in symptoms.”
–
